The Chemours Company Reports Second Quarter Results

Chemours posts flat sales, shrinking losses, but core profitability keeps sliding.

Risk flags

• ●Profitability is under sustained pressure, as evidenced by declining Adjusted EBITDA ($247 million vs. $260 million) and Adjusted Net Income ($64 million vs. $91 million), despite flat sales. This trend raises concerns about the company's ability to convert revenue into earnings.
• ●High leverage remains a structural risk, with net leverage at 4.4x and gross debt of $3.9 billion. While leverage has declined, the company is still exposed to refinancing and interest rate risks, especially if profitability does not recover.
• ●Segment-level margin compression, particularly in APM (Adjusted EBITDA Margin down from 14% to 8%), signals operational challenges that could persist and weigh on overall results if not addressed.
• ●Some headline claims, such as the precise impact of TiO2 price increases and the 8% APM Performance Solutions growth, are not fully substantiated by detailed numerical disclosures. This limits transparency and makes it harder for investors to verify management's narrative.

Bottom line

Chemours' Q2 2026 results show a company treading water: sales are flat, losses are shrinking, but core profitability continues to erode. Cash flow and leverage metrics improved, but high debt and weak margins remain unresolved risks. Management's narrative is measured and avoids hype, but some claims lack full numerical backup. The near-term outlook is cautious, with only modest growth projected and no signs of a turnaround in profitability. For investors, the most important takeaway is that while operational discipline is evident, the underlying earnings power of the business is still slipping. To change this assessment, Chemours would need to deliver sustained margin improvement and clearer evidence of pricing power translating into real profit growth.

Announcement summary

(NYSE: CC) The Chemours Company announced its financial results for the second quarter 2026, reporting Net Sales of $1.6 billion, approximately flat compared to the corresponding prior-year quarter. Net Loss attributable to Chemours was $274 million, or $1.81 per diluted share, compared with a Net Loss of $380 million, or $2.53 per diluted share, in the prior-year quarter. Adjusted Net Income was $64 million, or $0.42 per diluted share, and Adjusted EBITDA was $247 million compared to $260 million in the prior-year quarter. Free Cash Flows improved 128% year-over-year, with Free Cash Flow Conversion of 46% and net leverage declining to 4.4x. As of June 30, 2026, consolidated gross debt was $3.9 billion, with total liquidity of $1.6 billion. The company paid down €230 million of the outstanding tranche of the B-3 Euro-denominated Term Loan due August 2028. The company projects full year 2026 Net Sales to grow in the range of 1% to 5% over 2025, with Adjusted EBITDA between $775 million and $825 million, and capital expenditures anticipated to be between $250 million and $280 million.

Disagree with this article?